[Synthesis of rubomycin 13-tert-butoxycarbonylhydrazone and the study of its antitumor action].
13-Tert-butoxycarbonylhydrazone of rubomycin was prepared on interaction of rubomycin with tert-butoxycarbonylhydrazine. The new compound showed a high antitumor activity with respect to lymphosarcoma LIO-1 and Garding-Passey melanoma. The compound had no advantages over the initial rubomycin in the treatment of these tumors, was inferior to rubomycin with respect to its activity against leukemia P-388 and unlike rubomycin had practically no effect on leukemia L-1210.
D000818:Animals; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000627:therapeutic use / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D007928:Lethal Dose 50; D007942:Leukemia, Experimental / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D013997:Time Factors
C022111:daunorubicin 13-tert-butoxycarbonylhydrazone; D003630:Daunorubicin
Sintez 13-tert-butoksikrabonilgidrazona rubomitsina i izuchenie ego protivoopukholevogo deĭstviia.